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Abstract
Background: Eosinophilic esophagitis (EoE) has been defined as “asthma of the esophagus” for the large number
of similarities between the two diseases. Omalizumab is an anti-Immunoglobulin E (IgE) antibody currently
approved only in allergic IgE-mediated severe persistent uncontrolled asthma and in chronic spontaneous urticaria
unresponsive to antihistamines, but it has been tried in other diseases, too.
Case presentation: We present herein the case of a 13-year-old boy, affected from preschool age by severe
chronic allergic asthma poorly controlled despite a generous long-term therapy, and, since he was 8 years old, by
eosinophilic esophagitis, responsive to courses of strict elimination diet and semi-elemental diet, even if very
burdensome for his quality of life.
At the age of 11.5 years, for inadequate asthma control, he started to receive therapy with omalizumab. After the
first month and for the entire duration (18 months) of omalizumab treatment, asthma was well controlled, long-
term conventional therapy was gradually withdrawn and lung- function improved. Concerning EoE, after an
initial clinical but not histological remission during the first few months of treatment with omalizumab, the
patient experienced an exacerbation of gastrointestinal symptoms. Therefore, he started treatment with topical
steroids which was effective to improve gastrointestinal symptoms. However, EoE is still steroid-dependent.
Currently, he continues both treatments: omalizumab for asthma and topical steroid for EoE.
Conclusions: This case report confirms that omalizumab is an effective treatment in patients with severe
persistent, uncontrolled asthma. On the other hand, in our patient it did not produce persistent improvement
neither on symptoms nor on biopsy findings of EoE. The outcome of this case might indicate different pathogenic
mechanism(s) of the two diseases.
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Background
Eosinophilic esophagitis (EoE) has been defined as
“asthma of the esophagus” for the several similarities be-
tween the two diseases [1, 2]. The prevalence of both dis-
eases is increasing over time –as other atopic conditions-
and, they often coexist: asthma has been reported in
higher percentage (up to 80 %) in subjects with EoE [3].
Both asthma and EoE are chronic immune-mediated and
most likely antigen - driven conditions [2]. Food allergy
often precedes asthma and it seems to be driving EoE, in
children. In adult and teenagers, allergic sensitization to
aeroallergens is often associated not only with asthma but
also with EoE, worsening their prognosis [2]. Inflamma-
tion of mucosa and submucosa with a typical infiltration
by eosinophils is hallmark of both conditions [2]. Allergen
avoidance may improve symptoms in both diseases with-
out curing them [2].
On the basis of similarities it is reasonable to realize that
similarities “could mirror” also in therapy. Omalizumab is
a humanized monoclonal anti-Immunoglobulin E (IgE)
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antibody currently approved only in allergic IgE-mediated
severe persistent asthma and in chronic spontaneous urti-
caria unresponsive to antihistamines [4] but it has been
tried as off-label treatment in other diseases [5], in par-
ticular in some isolated cases of EoE with different results
as described in some previous reports [6–8]. We report
the case of a 13-year-old boy, affected by severe chronic
asthma inadequately controlled with high dose of inhaled
corticosteroids and montelukast and EoE treated with
omalizumab -for a longer period (18 months) than previ-
ous reports for EoE- with full remission of allergic asthma
but not of eosinophlic esophagitis.
Case presentation
A 13-year-old boy, affected by severe chronic asthma with
abnormal lung function: a forced expiratory volume in 1 s
(FEV1 < 80 %) of the predicted value before bronchodila-
tion with β2 agonist: salbutamol. The first respiratory
symptoms appeared when he was about two years old.
He had dust mites and olive pollen allergies -confirmed
by skin prick tests (average diameter of wheal for Derma-
tophagoides Pteronyssinus, Dermatophagoides Farinae,
and Olive pollen: 9, 7, and 5 mm, respectively) and specific
IgE levels (100, 82 and 68 IU/ml, respectively) and high
total IgE (1003 IU/ml) levels with normal eosinophil count
(110/mmc).
He performed long-term anti-asthma therapy with high-
dose inhaled corticosteroids (fluticasone up to 750 μg/day),
also associated with a leukotriene receptor antagonist (mon-
telukast) and sublingual specific immunotherapy (SLIT)
with dust mite extract (since he was 5 years old for 3 years
continuously) with poor disease control (without any precise
seasonal correlation) and reduction of FEV1 according
to GINA guidelines (Fig. 1) (http://www.ginasthma.org/
documents/1/Pocket-Guide-for-Asthma-Management-
and-prevention).
When he was 8 years old, for the appearance of gastro-
intestinal symptoms (nausea, vomiting, heartburn), after
endoscopy-biopsy of the upper digestive tract, eosinophilic
esophagitis was diagnosed (Fig. 2a and b).
The prick tests were positive to milk (average diameter
of wheal for milk extract 8 mm; α-lactoalbumin 10 mm;
β-lactoglobulin 7 mm; casein 6 mm; Prick by prick with
fresh milk 10 mm) and soy (5 mm).
He was placed on semi-elemental diet with benefit on
esophageal symptoms and a strict food allergens (milk,
dairy products and soy) avoidance, and histology (per-
formed after 3 months since the beginning of each therapy,
respectively at 9.3 and 10 years of age) but with heavy bur-
den on his quality of life. Symptomatic response to therapy
(improvement/impairment/no change) was assessed evalu-
ating changes of the patient’s answers concerning the fol-
lowing items: frequency of trouble swallowing; duration of
trouble swallowing (≥/< 5 min); pain when swallowing. Fur-
thermore, a visual dysphagia question addressed the sever-
ity of dysphagia when consuming food of 8 distinct
consistencies. Behavioural adaptations (avoidance, modifi-
cation, and slow eating of various foods) also were assessed
in the context of consuming 8 distinct food consistencies
[9]. Afterwards, courses of topical steroid therapy (oral
budesonide) were also carried out with symptomatic and
histological efficacy. The latter was detected after the sec-
ond (at 10.6 years of age), and the sixth run (under omali-
zumab, at 12.6 years). However, the effects (on both
symptoms and histology) were transient and the treatment
was sometimes complicated by oral candidiasis, for which
the therapy was interrupted and antimycotic treatment was
performed by patient.
Fig. 1 FEV1 (% predictive value) longitudinal profile in our patient. Changes in forced respiratory volume in 1 s (FEV1) over time are shown for
different treatments. FEV1 significantly improved during omalizumab therapy. The most representative detections are represented
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At the age of 11.5 years, for inadequate asthma control
(in the last 2 months he presented daytime symptoms 3 to
4 times/week, some night waking due to asthma, reliever
needed 2 to 3 times/week, limitation of his activities- e.g.
going upstairs- due to asthma) (http://www.ginasthma.org/
documents/1/Pocket-Guide-for-Asthma-Management-and-
prevention), he started to receive therapy with omalizumab.
According to technical data sheet, the dose and frequency
of dosing were guided by a nomogram that is derived from
the total serum IgE level and the body mass index (375 mg
subcutaneously every 2 weeks). After the first month of
treatment, conventional long-term therapy for asthma was
reduced up to the suspension (at the 4th month of omalizu-
mab therapy), with an improvement both in asthma symp-
toms and in spirometric parameters for the entire duration
of treatment (18 months) (Fig. 1). Broncodilatator revers-
ibility test remained positive over time, before and after
omalizumab therapy, with a significant increase in FEV1
after bronchodilator (salbutamol) indicating a reversible
airflow obstruction and supports the diagnosis of asthma
(http://www.ginasthma.org/documents/1/Pocket-Guide-
for-Asthma-Management-and-prevention).
Regarding EoE, during the first three months of treatment
the patient presented in clinical remission even if not ac-
companied by histological remission (endoscopy performed
at the 3rd months of treatment). Afterwards, he experienced
an exacerbation of gastrointestinal symptoms with confirm-
ation of eosinophilic infiltrates in the esophageal mucosa
(endoscopy at the 7th month of treatment). Therefore, he
performed treatment with topical steroids (galenical oral vis-
cous budesonide) with improvement of nausea and vomit-
ing. In detail, we used a product prepared by the chemist in
the laboratory of our pharmacy. The product was made
mixing a vial of budesonide (1 mg/2 ml) with 5 g of sweet-
ener (2.5 g of aspartame and 2.5 g dextrose) [10, 11].
On the other hand, at the 18th month of omalizumab
therapy the patient continues to have a good asthma con-
trol according to GINA assessment (http://www.ginasth-
ma.org/documents/1/Pocket-Guide-for-Asthma-Manage-
ment-and-prevention) without other anti-asthmatic therapy
and his EoE is steroid-dependent. He is going on treatment
with omalizumab s.c. and viscous budesonide per os.
Discussion
The patient, with severe respiratory and esophageal
symptoms, had a quality of life seriously compromised
by his allergic diseases. Despite a heavy long-term treat-
ment with high dose of inhalant steroids combined
antileukotriene, his asthma remained poorly controlled;
the semi-elemental diet and the strict food avoidance of
milk and dairy products, although had provided an im-
provement, though transient, in esophageal symptoms,
were very burdensome for the patient.
Omalizumab was effective therapy for severe persistent
asthma in our patient, according to its conventional indi-
cation, but it did not produce persistent clinical improve-
ment nor endoscopic and histological changes of his EoE.
Few cases of EoE treated with omalizumab (n = 2 [6],
n = 9 [7], n = 15 [8]) have been reported in literature.
Authors of the first two studies described improvement in
symptoms without a reduction of oesophageal eosinophils
in all patients treated with omalizumab and food avoidance
[6, 7]. The third one, a pilot study, open label, on 15 patients
treated with omalizumab for 12 weeks, maintaining dietary
restriction, found a histological and clinical improvement
only in 33 % of the patients (subjects with low peripheral
blood absolute eosinophil count) [8].
In our patient, different than other cases previously re-
ported, no dietary restriction was maintained to verify the
efficacy of the only treatment with omalizumab without
risk of confounding. Dietary restriction is one of the main
treatment options in patients with EoE and food allergy.
Fig. 2 Esophageal histology. An evident eosinophilic cellular
infiltrate was encountered in the esophageal epithelium; intercellular
oedema as well as basal zone hyperplasia were also appreciable (a)
[Haematoxylin and Eosin staining (H&E), original magnification x200];
sometimes eosinophils were organized in micro-abscesses (b)
(H&E, original magnification x 400)
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Therefore, in the previous studies it is likely a possible
overlap of effects of two treatments (food avoidance plus
omalizumab).
This is only a single clinical case. However, considering
the limitations of assumptions based on it, the therapeutic
failure of omalizumab in EoE of our patient might high-
light that omalizumab probably does not work on
allergen-specific IgE-mediated pathogenic mechanism of
EoE, or at least not mainly. In EoE allergic sensitization
drives the formation of allergen-specific both IgE and T
cells and they potentially have independent roles in the
underlying disease pathogenesis [12]. Therefore, our data
indicate that asthma and EoE, even sharing a similar aller-
genic features, are likely mantained by different patho-
genic mechanisms, which need to be better understood.
In literature a unique case of EoE induced by SLIT to
pollens is described. [13] A seasonal and geographical
pattern of EoE which may be compatible with increased
airborne allergen was reported, too [14, 15].
Cautiously, considering the literature paucity about a
possible correlation between EoE and SLIT, it might be
hypothesized that, likely, sublingual dust mite immuno-
therapy might cause or exacerbate EoE by exposing the
esophagus to host dust mites allergens (HDM) every
day. However, investigations are needed.
Notwithstanding, in our patient, esophageal symptoms
were correlated temporally to food allergen-exposure
and not to airborne (and in particular to HDM) expos-
ure (esophageal symptoms appeared about three months
after the end of SLIT to HDM).
We are aware of the limitations of assumptions based
on one case only, but we report our experience because
in our knowledge this is the first case of EoE treated
with omalizumab for so a long period (18 months) and
it may help to elucidate the pathophysiology of EoE and
to select patients affected with EoE that could benefit of
anti-IgE treatment. In the recent pilot study [8] omalizu-
mab –induced remission of EoE was limited to subjects
with low peripheral blood eosinophil count. Instead, our
patient, despite a normal-low eosinophilic serum count
before and during the entire duration of treatment, did
not respond to omalizumab.
Conclusions
In conclusion, the Th2 cytokines, IL-13 and IL-4, re-
main, currently, the most promising antieosinophil tar-
gets also in EoE and more studies are required in order
to clarify the possibility of new therapeutic approaches
such as omalizumab for EoE management.
The present case report confirms that omalizumab is an
effective treatment in patients with severe persistent, un-
controlled asthma. On the other hand, in our patient it
did not produce persistent improvement neither on symp-
toms nor on biopsy findings of EoE. The outcome of this
case might indicate different pathogenic mechanism(s) of
the two diseases. Well-designed and large studies are
needed.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
EoE: eosinophilic esophagitis; FEV1: forced expiratory volume in 1 second;
H&E: haematoxylin and Eosin; HPF: high power fields; IgE: immunoglobulin E.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GBP & SA: Study conception and design of the manuscript. SA and GBP: Writing
up of first draft of the paper. SC, GM, AI, LC, FC, MV, MMDG & GC: Critical
revision of the article. All authors read and approved the final manuscript.
Author details
1Department of Pediatrics- Allergy Unit, University of Messina, Via Consolare
Valeria- Gazzi, 98124 Messina, Italy. 2Department of Pediatrics-
Gastroenterology Unit, University of Messina, Via Consolare Valeria- Gazzi,
98124 Messina, Italy. 3Department of Human Pathology, University of
Messina, Via Consolare Valeria- Gazzi, 98124 Messina, Italy. 4Department of
Dermatology, University of Messina, Via Consolare Valeria- Gazzi, 98124
Messina, Italy. 5Department of Pediatrics, II University of Naples, via De
Crecchio 4, 80138 Naples, Italy.
Received: 21 December 2015 Accepted: 7 March 2016
References
1. Arora AS, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus?
Clin Gastroenterol Hepatol. 2004;2:523–30.
2. Virchow JC. Eosinophilic esophagitis: asthma of the esophagus? Dig Dis.
2014;32:54–60.
3. Jyonouchi S, Brown-Whitehorn TA, Spergel JM. Association of eosinophilic
gastrointestinal disorders with other atopic disorders. Immunol Allergy Clin
North Am. 2009;29(1):85–97.
4. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma
in adults and children. Cochrane Database Syst Rev. 2014;1, CD003559.
5. Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, et al.
Omalizumab in children. Paediatr Drugs. 2014;16(6):491–502.
6. Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, et al. Omalizumab
in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr.
2011;170:1471–4.
7. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, et al.
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
J Allergy Clin Immunol. 2007;120:594–601.
8. Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, et al.
A pilot study of omalizumab in eosinophilic esophagitis. PLoS ONE. 2015;10:
e0113483.
9. Grudell AB, Alexander JA, Enders FB, et al. Validation of the mayo dysphagia
questionnaire. Dis Esophagus. 2007;20:202–5.
10. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, et al.
Viscous topical is more effective than nebulized steroid therapy for patients
with eosinophilic esophagitis. Gastroenterology. 2012;143:321–4.
11. Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is
effective in children with eosinophilic esophagitis in a randomized,
placebocontrolled trial. Gastroenterology. 2010;139:418–29.
12. Wechsler JB, Bryce PJ. Allergic mechanisms in eosinophilic esophagitis.
Gastroenterol Clin North Am. 2014;43(2):281–96. doi:10.1016/j.gtc.2014.02.006.
Epub 2014 Mar 22.
Arasi et al. Italian Journal of Pediatrics  (2016) 42:32 Page 4 of 5
13. Miehlke S, Alpan O, Schröder S, Straumann A. Induction of eosinophilic
esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol.
2013;7(3):363–8.
14. Moawad FJ, Veerappan GR, Lake JM, Maydonovitch CL, Haymore BR, Kosisky
SE, et al. Correlation between eosinophilic oesophagitis and aeroallergens.
Aliment Pharmacol Ther. 2010;31:509–15.
15. Hurrell JM, Genta RM, Dellon ES. Prevalence of esophageal eosinophilia
varies by climate zone in the United States. Am J Gastroenterol. 2012;107:
698–706.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Arasi et al. Italian Journal of Pediatrics  (2016) 42:32 Page 5 of 5
